Insider buying by the new CEO of this buyer of biopharmaceutical royalties, puts this name on my radar.
After getting a 'win' earlier this week on an acquisition, let's highlight a few similar names in my portfolio.
Let's check the charts after this biotech reports earnings and snags a new 'buy' recommendation.
It looks as though the answer could be yes as the shares of the biopharmaceutical company have built a nice base.
Here's where traders could go long.
Let's review three pharma companies based outside the U.S. that promise reasonable valuations and solid dividend yields.
I've noticed that biotech has been one area of strength lately.
Here's where aggressive traders could go long.
There are reasons besides their cash positions to think these companies could see their stocks improve going forward.
Let's see how to play Aldeyra Therapeutics, a promising small-cap company out of Massachusetts.